The incidence and type of pathology causing a prolonged prothrombin time and clinical bleeding episodes were assessed in a multicentre study of 1109 patients receiving cefotetan, a N-methylthiotetrazole (NMTT), or equivalent antibiotics. There was no significant difference in the incidence of a prolonged prothrombin time (9-9% with cefotetan, 8-0% with comparable antibiotics) of clinical bleeding episodes. However, prothrombin time increases of greater than 12 seconds were significantly (p = 0 002) greater with cefotetan (3-8%) than with comparators (0-8%). In both antibiotic groups increases in prothrombin time were more likely following surgery and in patients who were older, with a high platelet count, low albumin, or higher urea and creatinine concentrations. All antibiotic treatment can be associated with prolonged prothrombin times and new agents should always be assessed in a large multicentre study before the practical, clinical importance of haemostatic defects can be defined.
There are numerous causes of acquired defects of the haemostatic mechanism, usually associated with multisystem disease, or As the prothrombin times were measured in 16 different laboratories using different types of thromboplastin, the normal range varied between 11 and 16 seconds. Prolongation of the prothrombin time was defined as a five second increase outside the upper limit of the normal immediately before the study. Only 226 (20-4%) had received other antibiotics in the four weeks immediately before this study.
Of the 1109 patients randomly selected to receive either cefotetan (CTT) or comparator antibiotics, six were withdrawn from the analysis as they received warfarin with profound effects on prothrombin time. From the 1109 patients initially selected, 1005 had two or more prothrombin times performed. Of these, 9 5% had two measurements, 26-6% had three, 56-2% had four and 7-8% had five or more (the mean was 3-9).
The incidence ofchanges in the prothrombin time ofover five seconds for all ofthe patients is shown in table 2. This also shows the subgroup of patients with an abnormally prolonged prothrombin time before treatment who developed further increases of over five seconds during treatment. The incidence of increased prothrombin time was not significantly different between the two groups. When the patients who developed an increase of prothrombin time of over 12 seconds are analysed, however, this is significantly higher in the group taking cefotetan (p = 0-002) (table 3) .
Out of the total of 1109 patients, vitamin K was only added to 77 patients-A5 patients in the cefotetan group and 32 in the comparator group. Of the 77 additions, 27 were as a result ofnormal practice or an abnormal prothrombin time before antibiotics were started. In the remaining 50 cases vitamin K was added as a result of a rise of prothrombin time (30 taking cefotetan, 20 taking comparators) during treatment and resulted in a return to normal prothrombin time, and yet some with larger rises still had no vitamin K added.
An analysis of all of the patient characteristics and laboratory data available showed that six clinical and laboratory variables were significantly related to the development of a prolonged prothrombin time ( Renal impairment, as well as affecting the elimination of antibiotic, may predispose to variable coagulation factor deficiencies, hepatic cell dysfunction, and uraemic enteritis, all of which can contribute to a prolonged prothrombin time.'9 Studies of the newer agents, especially the cephamycins, moxalactam, and cefotetan, have commonly included such compromised patients. We have shown, however, that all antibiotics, especially when given to patients in the above high risk categories, may coincidentally be associated with a prolonged prothrombin time, predisposing in some cases to clinical bleeding events. Prothrombin time alone is a poor indicator of vitamin K state and it may be appropriate to administer vitamin K to patients with the defined risk factors In patients without these risks the NMTT containing antibiotic, cefotetan, did not cause more rises of prothrombin time than alternative antibiotics. Single case reports of antibiotic associated hypothrombinaemia, which have been repeatedly reported, must now be judged against similar control groups receiving comparative antibiotic treatment. Only when such data are available can the true incidence and clinical importance of such events be judged. The results provided in this paper should provide guidance regarding the types of patients in the high risk categories.
